research LB943 Tofacitinib treatment of inflammatory skin conditions in patients with Down Syndrome
In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.


